drugset / Trial / NCT02379247
BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Investigate the use of BYL719 (alpelisib) as combination therapy with Nab-Paclitaxel in locally recurrent or metastatic HER-2 negative breast cancer.
Timeline
- Start
- 2015-02
- Primary completion
- 2017-09-21
- Completion
- 2022-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpelisib | Small molecule | 250 mg | Oral |
| Subject | Alpelisib | Small molecule | 300 mg | Oral |
| Subject | Alpelisib | Small molecule | 350 mg | Oral |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |